Live Breaking News & Updates on Development Therapeutic Areas

Stay updated with breaking news from Development therapeutic areas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pfizer (PFE) and Astellas Report Phase 3 Study Shows XTANDI plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Pfizer (PFE) and Astellas Report Phase 3 Study Shows XTANDI plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chris Boshoff , Ahsan Arozullah , Astellas Pharma Inc , Pfizer Inc , Head Of Development Therapeutic Areas , Drug Administration , Pfizer Global Product Development , Astellas Pharma , Chief Development Officer , Rare Disease , Pfizer Global Product , Senior Vice President , Development Therapeutic Areas ,

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer  Pfizer and Astellas announce positive top-line results from Phase 3 EMBARK trial      Addlestone UK, 17 March, 2023&nb. ....

United Kingdom , United States , Northern Ireland , Great Britain , Chris Boshoff , Ahsan Arozullah , Astellas Pharma Ltd , Drug Administration , Pfizer Global Product Development , Lab Abnormalities , Astellas Pharma Inc , Head Of Development Therapeutic Areas , Medivation Inc , Nonmetastatic Prostate Cancer , Astellas Pharma , Senior Vice President , Development Therapeutic Areas , Chief Development Officer , Rare Disease , Pfizer Global Product , South America , Non Metastatic Hormone Sensitive Prostate Cancer , High Risk Biochemical Recurrence , Important Safety Information , Product Characteristics , Reversible Encephalopathy Syndrome ,

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Kenji Yasukawa , Chris Boshoff , Ahsan Arozullah , American Society Of Clinical Oncology , Prnewswire Pfizer Inc , Drug Administration , Pfizer Global Product Development , Lab Abnormalities , Astellas Inc , Exchange Commission , Astellas Pharma Inc , Pfizer Inc , Astellasastellas Pharma Inc , European Union , Head Of Development Therapeutic Areas , Medivation Inc , Astellas Pharma , Chief Development Officer , Rare Disease , Pfizer Global Product , Senior Vice President , Development Therapeutic Areas , South America , Non Metastatic Hormone Sensitive Prostate Cancer , High Risk Biochemical Recurrence ,

Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the Phase. ....

United States , Kenji Yasukawa , Ahsan Arozullah , Zhou Fangjian , American Society Of Clinical Oncology , Sun Yat Sen University Cancer Center , China National Medical Products Administration , Astellas Pharma Inc , Fudan University Shanghai Cancer Center , Head Of Development Therapeutic Areas , Head Of Urology Department , Sun Yat Sen University , Medivation Inc , Astellas Pharma , Senior Vice President , Development Therapeutic Areas , Urology Department , Sun Yat Sen , Vice President , Multi Disciplinary Team , Symptomatic Skeletal Event , Important Safety Information , Focus Area Approach , American Society , Prostate Cancer , Accessed September ,

Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced The Lancet published detailed results. ....

United States , Kenji Yasukawa , Ahsan Arozullah , Przegl Menopauzalny , Genevieve Neal Perry , J Public Health , School Of Medicine Department Obstetrics , Health Qual Life Outcomes , Astellas Pharma Inc , American College Of Obstetricians , Head Of Development Therapeutic Areas , Prnewswire Astellas Pharma Inc , American College , Medicine Department , Short Form , Total Score , Patient Global Impression , Sleep Disturbance , Menopause Specific Quality , Senior Vice President , Development Therapeutic Areas , Clinical Endocrinology , Focus Area Approach , Equal Life , Penn Ovarian Aging Study , Astellas Pharma Inc ,